September #39 : Uncertain-teens - by Lark Lands, PhD

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents

Talking 'Bout Their Generation

Youth to Youth

Bargaining Power

Growing Up in Public

Liver Worst

Family Tree

Blood Lines

S.O.S.

To the Editor

And on the 7th Day...

In the Sack

Vertex Vortex

Pump and Grind

Baby Gap

You Can’t Touch This

Aloe Can You Go?

Death by Bureaucracy

Bubonic Tonic

Say What

Say What

All Apologies

Plenty of Nothing

Rough Cuts

POZ Picks

Spin and Needles

No Miss Manners

HIV Confidential

Making a Scene

Obits

Presidential Nemesis

Are the Kids Alright?

Kid Gloves

Prime-Time Lives

Don’t Make Me Over

Confessions of a Jerk

Life Lessons

Quality Time

Valuable Kitchen Tool

Better Safe Than Sushi

The Heart of the Matter

To C or Not to C

The Circle Game

Youth on Drugs

Uncertain-teens

Making the Grade

Finger on the Pulses

Fountain of Youth

Where to find it

Reality Check

Leftovers



Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV


email print

September 1998

Uncertain-teens

by Lark Lands, PhD

Drug dosage divergences

Do HIV meds work the same in adolescents as in adults? Unfortunately, the knowledge base on this question is still in its infancy. Very few of the clinical trials done to date have included teenagers, and even those that did had no more than a handful. The current view—based on minimal studies—is that there are no real metabolic issues that would require treatment in most teens to be different from that in adults. In general, dosage recommendations are identical, and all the drugs approved for adults are also approved for adolescents.

However, Hoffman notes that an evaluation procedure called the Tanner system should be used to identify the stage of puberty, since that will affect dosing (see “Making the Grade,” p. 108). The development of breasts, pubic hair and genitalia is visually assessed, and those defined as Tanner stage 1 (prepubertal) or Tanner stage 2 (early changes) are dosed as children. Those in Tanner stages 4 or 5 are dosed as adults. For Tanner stage 3 (transitional period), dosage depends on whether or not the growth spurt has occurred. Unfortunately, not all clinicians are aware of the need to do this careful staging, so dosing mistakes can result.

A federal study of adolescents with HIV, now enrolling in 13 cities, may eventually shed light on the many unanswered questions about whether—and how—both the disease and its treatments affect this age group differently from adults.




[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Are you buying holiday gifts that raise HIV/AIDS awareness?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.